Menu Search
Equities

Biotest AG

BIOG:DEU

Biotest AG

Actions
  • Price (EUR)41.20
  • Today's Change0.20 / 0.49%
  • Shares traded11.00
  • 1 Year change-2.83%
  • Beta--
Data delayed at least 15 minutes, as of Nov 21 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Biotest AG is a Germany-based provider of plasma proteins and biological drugs. The Company, with a chain that extends from pre-clinical and clinical development to worldwide marketing and distribution, mainly specializes in the areas of clinical immunology, hematology, and intensive care medicine. It develops, manufactures, and markets immunoglobulin, coagulation factors, and albumins based on human blood plasma. These are used for diseases of the immune and hematopoietic systems. In addition, the Company develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus, which are produced by recombinant technologies.

  • Revenue in EUR (TTM)707.00m
  • Net income in EUR68.50m
  • Incorporated2006
  • Employees2.46k
  • Location
    Biotest AGLandsteinerstr. 5DREIEICH 63303GermanyDEU
  • Phone+49 61038010
  • Fax+49 6 103801150
  • Websitehttps://www.biotest.com/
More ▼

Institutional shareholders

0.08%Per cent of shares held by top holders
HolderShares% Held
Arvernus Capital AGas of 30 Sep 20238.93k0.05%
Banor Capital Ltd.as of 30 Nov 20214.45k0.02%
BANTLEON Invest GmbHas of 30 Nov 20232.00k0.01%
Data from 30 Sep 2023 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.